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Abstract:    Prostate cancer is the second most common male malignancy in the 
western world an increasing incidence in an ageing population.   Treatment of 
advanced prostate cancer relies on androgen deprivation. Although the majority of 
patients initially respond favourably to androgen deprivation therapy, the mean time 
to relapse is 12-18 months.  Currently there are few treatments available for men who 
have developed resistance to hormone therapy, due to the lack of understanding of the 
molecular mechanisms underlying development of this disease.   
Recently, however, major advances have been made in understanding both 
androgen receptor (AR) dependent and independent pathways which promote 
development of hormone resistant prostate cancer.  This review will focus on 
modifications to the AR and associated pathways.  Molecular modifications to the 
androgen receptor itself, e.g. mutations and/or amplification, although involved in the 
development of hormone resistance cannot explain all cases. Phosphorylation of AR, 
via either Ras/MAP kinase or PI3K/Akt signal transduction pathways, have been 
shown to activate AR in both a ligand (androgen) dependent and independent fashion. 
During this review we will discuss the clinical evidence to support AR dependent 
pathways as mediators of hormone resistance. 
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INTRODUCTION 
Prostate cancer is an extremely prevalent disease with 25,000 new cases 
diagnosed in the UK and 198,000 in the USA each year [1]. Despite progress in early 
diagnosis, due to increased awareness and PSA screening, prostate cancer remains the 
second leading cause of male cancer specific mortality in western countries [2]. 
Treatment of prostate cancer varies depending on the stage of the disease, 
treatment of advanced or metastatic disease relies on androgen deprivation therapy, 
the principle of which has remained unchanged for the past 55 years [3].  Androgen 
deprivation can be achieved surgically, by castration, or chemically, by suppression of 
androgen production using luteinising hormone-releasing hormone (LH-RH) agonists.  
This may be combined with an androgen receptor (AR) antagonist to achieve maximal 
androgen blockade. AR antagonists inhibit the action of adrenal steroids [3] and block 
the “flare” caused by the initial stimulatory action of LH-RH agonists on steroid 
production.  Initial response rates to androgen deprivation therapy are high, however 
patients generally relapse within 18-24 months [3] with rising circulating PSA 
concentrations characteristic of renewed tumour growth.  This is indicative of the 
development of hormone refractory prostate cancer, a process also termed androgen 
escape.  At present, there are no effective treatment options for patients who develop 
androgen escape.  Although clinical trials with only antiandrogens therapy have been 
demonstrated to improve quality of life of the patient although it does not alter 
survival [4].  In addition alternative approaches such as chemotherapy and 
radiotherapy do not provide significant disease control, so treatment is generally 
palliative aimed at maintaining quality of life by decreasing bone pain and urinary 
tract obstruction [3]. The development of androgen escape is therefore one of the most 
significant events in the progression of prostate cancer, resulting in increased risk of 
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morbidity and reduced survival.  The median survival of patients following 
development of androgen escape is 12 months [3].  The high rate of prostate cancer 
mortality is thus strongly linked to both development of androgen escape and a lack of 
alternate therapies.  
The lack of novel and effective therapies to treat androgen escape is due to poor 
understanding of the molecular mechanisms underlying development of both the 
primary disease, and more particularly, those events which drive androgen escape. 
Previously the majority of research investigating the development of androgen escape 
focused on the AR, however, more recently research has focused on distinct 
molecular pathways which modulate AR function [5].  Identification of such 
pathways will provide novel therapeutic targets for treatment of patients with 
androgen escape [3]. 
ACTIVATION OF THE ANDROGEN RECEPTOR 
AR ligands belong to a family of steroid hormones known as androgens and include 
both testosterone and dihydrotestosterone (DHT).  Both testosterone and DHT can 
bind to the AR although DHT has a higher binding affinity (approximately 10 times) 
than testosterone, and is consequently the primary androgen bound by AR [5].  
Testosterone is produced by testicular Leydig cells, and is converted to DHT by 5α-
reductase type 2 when it enters prostate epithelial cells.  
Ligand free AR is sequestered in the cytoplasm bound to heat shock proteins 
(HSP70 & HSP90).  Heat shock proteins function to stabilise the AR during folding, 
protecting it from degradation. DHT binds to the AR inducing a conformational 
change, which allows dissociation of heat shock proteins (HSP-70 and HSP-90). The 
AR then forms a homo-dimer and is phosphorylated at several sites including the 
PKC phosphorylation sites Ser81 and Ser650, plus Ser662 Ser93, Ser803, but excluding the 
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MAP kinase and AKT specific phosphorylation sites (Ser515 and Ser210, 
respectively)[6,7]. This phosphorylation of the receptor stabilises the ligand/receptor 
homodimer, marking the ligand-receptor complex for translocation to the nucleus.  
The AR-ligand complex then initiates gene transcription by binding to specific 
androgen response elements (AREs) in the promoter regions of target genes. 
Following DNA binding, the RNA polymerase machinery is recruited to the initiation 
site and transcription of AR regulated genes begins [5] (Fig. 1).  
HORMONE RESISTANT PROSTATE CANCER 
The function of androgen deprivation therapy is to prevent the activation of AR 
mediated gene transcription by removing or competing with the endogenously 
produced steroids. Failure of androgen deprivation therapy, observed in hormone 
resistant prostate cancer, was therefore logically linked to modification of the action of 
the AR. Early research into the failure of androgen deprivation therapy centred on 
investigations of molecular alterations to the AR.  However, more recently, there has 
been a shift to suggest that post-translational modification of the AR, via 
phosphorylation at specific sites may influence the development of androgen escape.  
In the remainder of this review we summarise our current understanding of the 
molecular mechanisms underlying androgen escape with particular emphasis on 
evidence from clinical observations in human prostate cancers.  
 
 
ANDROGEN RECEPTOR MUTATIONS 
The first AR mutation was identified, in 1992, in LNCaP cells at T877A and 
was closely followed by H974Y in the hormone refractory prostate cancer xenograft 
CWR22.  Both these mutations were in the AR ligand-binding domain (LBD) [8].  In 
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vitro research has demonstrated that AR mutations in the ligand binding domain alter 
ligand binding affinity and receptor transcriptional activity [9,10].  Activation of the 
mutated AR by non-androgenic steroids (corticosteroids) or indeed by androgen 
antagonists [5] mirror similar findings of tamoxifen resistance in  breast cancer.  
Specific mutations of the AR are associated with hydroxyflutamide and bicalutamide 
resistance [11,12].  Taplin et al. demonstrated that AR mutaions may occur in 
response to hydroxyflutamide therapy.  Patients on combined androgen blockade with 
hydroxyflutamide as the AR antagonist, had mutations in the AR cause 
hydroxyflutamide to stimulate growth.  However if therapy was changed to 
biclutamide growth was again inhibited.  However patients that were not on 
hydroxyflutamide did not develop these mutations [12].  AR mutations in the hinge 
region have also been identified that impact on the effectiveness of therapy and are 
thought to play a role in the emergence of hormone refractory disease [13].  However, 
AR mutations are found more commonly in vitro than in vivo, AR mutations are 
detected in 10-20% of prostate cancer specimens [5,11] with mutations more common 
in hormone escaped specimens compared to hormone sensitive specimens [5,14]. 
Mutations in the LBD are more common in primary tumours compared to mutations 
in the N-terminal domain of androgen escaped tumours [15].  N-terminal mutations 
may allow AR binding interaction with co-activators without activation by a ligand, 
therefore providing a possible mechanism of androgen escape, whereas mutations in 
the LBD have been documented in vitro to allow activation of the AR by 
corticosteroids or AR antagonists [15-17].  Interestingly AR mutations are more 
commonly found in distant metastases [18] than in local relapses, even following 
development of hormone resistance, this may reflect a role of AR mutations in 
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promoting disease spread or may simply be a consequence of an increasingly unstable 
genome due. 
AR mutations, in clinical prostate cancer, occur prior to androgen escape but do 
not preclude response to hormonal therapy. In our opinion, mutations in the ligand-
binding domain may be responsible for the development of androgen escape in a 
small sub-group of patients. The low frequency of such mutations is likely to preclude 
the development of therapies specifically targeting AR mutations although this group 
might benefit from the use of antisense oligonucleotides directed against AR to down 
regulate expression of the mutant receptor [5]. 
ANDROGEN RECEPTOR AMPLIFICATION AND PROTEIN OVER 
EXPRESSION 
AR gene amplification has been associated with hormone escape [19] and 
recently amplification rates have been shown to rise significantly in the transition 
from hormone sensitive to hormone resistant disease (0-5% in hormone sensitive 
tissue and 20-30% in hormone resistant tissue) [20]. Evidence from a number of 
sources suggests that, unlike chromosomal duplication (aneusomy), gene 
amplification results in increase protein expression via gene disregulation.  We 
recently demonstrated that AR gene amplification was seen in 20% of hormone 
escaped prostate cancer and the majority of these cases had a corresponding increase 
in AR protein expression (80%). However the remainder of cases in our cohort who 
acquired AR gene amplification on the transition to hormone escape had no increase 
in AR protein expression.  Therefore AR gene amplification does not always result 
in increased AR protein expression [20].  In the same study we identified a further 
22% of cases that had increased AR expression, in the absence of AR amplification 
[20].  Although first impressions suggest that the significant event in development of 
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hormone escape is an increase in AR expression and not AR amplification, further 
analysis suggests this might not be the case.  It is AR amplification and not AR 
protein expression levels that influences patient survival in our cohort (Fig 2). This 
may be due to gene amplification being able to detect those cases with marked 
protein over expression more accurately than immunohistochemistry, supporting the 
hypothesis that AR over expression is important in AIPC.  In breast cancer HER2 
studies it has been demonstrated that HER2 gene amplification is the better predictor 
of survival, and is linked to marked increases in protein expression (over 100 fold). 
A study earlier this year using xenograft models, demonstrated that increasing AR 
protein expression induced androgen escape independent of AR amplification [21]. 
However, this does not reflect the mechanism of AR up regulation in clinical 
prostate cancers. More significantly this study also demonstrated that high AR 
protein expression sensitises prostate cancer cells to low circulating levels of 
androgens and enables the AR to be activated.  This suggests that by increasing the 
dose of anti androgen therapy it may be possible to inhibit progression to androgen 
escape.  However animal experiments have demonstrated that increased AR 
expression levels may allow anti-androgens to function as weak agonists, resulting 
in activation of the AR[21].   
In conclusion although the significant event in the development of androgen 
escape is an increase in AR protein expression, it appears that only cases with AR 
amplification can express AR protein at levels that are high enough to have 
functional relevance.  Increased AR expression may explain the development of 
hormone escape prostate cancer in only 20-30% of cases i.e. those who develop AR 
amplification, requiring the existence of alternative mechanisms to explain the 70-
80% of AIPC cases with no AR gene amplification.  Conversely AR gene 
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amplification may provide a powerful diagnostic tool for targeting AR over 
expression. 
ANDROGEN RECEPTOR ACTIVATION BY PHOSPHORYLATION 
In 1990 van Laar et.al. were the first to report phosphorylation of the AR[22].  
When AR is first synthesised it in a non-phosphorylated state, however after about 15 
min, even in the absence of a ligand it becomes phosphorylated at a few sites. When 
DHT binds to the AR it promotes recruitment of protein kinases resulting in 
phosphorylation of multiple serine residues (Ser 80, 93 and 641)[22].  This 
phosphorylation protects the AR from proteolytic degradation and stabilises AR 
homodimers [22].  In addition to the protective and stabilisation role of AR 
phosphorylation, evidence is now emerging that demonstrates phosphorylation of the 
AR at specific sites can influence transactivation [6]. AR transcriptional activity 
correlates strongly with phosphorylation of specific serine residues (e.g. Ser 213, 506 & 
650)[23], only one of which is phosphorylated following DHT binding. 
Phosphorylation of the AR therefore appears to serve multiple functions, including 
both activation and stabilisation. It is currently unclear whether differing functions are 
linked to different phosphorylation sites or whether phosphorylation at certain sites is 
pluripotent. However, since phosphorylation of the receptor can be induced by 
multiple mechanisms, it is likely that AR phosphorylation is a multistage process. 
In the physiological situation phosphorylation by MAP and Akt kinases 
sensitises the AR to low circulating levels of DHT such as those present during 
maximum androgen blockade [23].  This sensitisation allows low levels of androgens 
or indeed alternative steroids (e.g. oestrogen or anti androgens) to induce 
phosphorylation at specific sites required for translocation of the AR to the nucleus. 
Several proteins have previously been demonstrated to phosphorylate AR in vitro, 
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resulting in increased AR transactivation, including MAP kinase, Akt and Protein 
Kinase C (PKC)(Fig 3) [23,24].  It is unclear at the moment whether phosphorylation 
by these kinases occurs prior to DHT binding or if this is a separate event that occurs 
following translocation to the nucleus to increase AR transcriptional activity at sub-
optimal DHT concentrations. 
MAP kinase levels are raised in hormone refractory cell lines.  Phosphorylation 
of the AR by MAP kinase, positively modulates expression of AR target genes, helps 
the recruitment of AR co-factors and increases prostate cancer cell growth [23]. 
Activated MAP kinase correlates with advanced stage and grade in prostate cancer 
and cell line studies demonstrate that MEK and MAP kinase are expressed and 
activated during prostate cancer progression [25].  Cell line studies also demonstrate 
that transfection with Ras results in increased expression and activation of MAP 
kinase resulting in the development of hormone escape [26]. It has been demonstrated 
in vitro using LNCaP cells that phosphorylation of AR at Ser515 by MAP kinase 
results in hyper-sensitisation to low levels of the synthetic androgen R1881 [26].  It 
therefore may be possible that during maximum androgen blockade in the 
physiological situation, that AR phosphorylation by MAP kinase induces 
hypersensitivity to DHT and also increases recruitment of AR co-factors and AR 
transcription activity.. 
Akt also known as protein kinase B, is a downstream member of the 
PI3K/PTEN cascade, a pathway with an important role in cell growth, adhesion and 
migration in a variety of cell types [27].  Akt is frequently activated in cancer cells 
and provides not only growth and survival signals for prostate cancer cells, but also 
modulates AR activity via phosphorylation (Fig. 3)[27].  There are 3 members of the 
Akt family, Akt 1, 2 and 3, and there is evidence that the 3 Akt isoforms may play 
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different roles in the development of hormone resistant breast cancer via interactions 
with the oestrogen receptor.  Akt may play a similar role in the development of 
androgen escape [28] as Akt has been demonstrated to phosphorylate the AR at Ser210 
and Ser790 and to modulate its transcriptional activity in prostate cancer cell lines (Fig. 
3) [29]. During androgen ablation or anti androgen treatment the LNCaP cells 
undergo growth arrest and apoptosis, and up-regulation of Akt activity appears to 
compensate for this [30].  Androgen independent LNCaP cells have high basal Akt 
activity (more than 20 fold higher than sensitive cells)[27], suggesting that removal of 
androgens by androgen deprivation therapy may result in increased activation of the 
PI3K pathway and promote development of androgen escape [29]. This hypothesis is 
supported by data that demonstrates that up-regulation of the PI3K cascade upon loss 
of androgen signalling contributes to failure of androgen ablation therapy [31]. 
In vivo the PI3K/Akt pathway may be up-regulated due to loss of PTEN which 
acts by dephosphorylating inositol lipids at the D3 position of the inositol ring 
reducing Akt activation [32]. PTEN deletions or inactivating mutations, result in Akt 
activation, which can induce cellular transformation [32].  Inactivating PTEN 
mutations are commonly found in prostate cancer and loss of PTEN expression is 
associated with increased risk of recurrence[32]. We hypothesise that loss of PTEN 
function or expression, combined with amplification and increased expression of 
PI3K results in increased Akt expression and activation, resulting in increased 
prostate cancer cell survival and growth and promoting the development of androgen 
escape. 
In summary, data gained predominantly from in vitro studies, suggest that over-
expression and activation of Akt can trigger prostate cancer androgen escape via 
activation of AR. Akt expression in tumours is significantly higher than in BPH, and 
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the intensity of Akt expression correlates with PSA levels [28].  It has also been 
reported that only 10% of well-differentiated prostate tumours strongly express 
phosphorylated Akt compared to 92% of poorly differentiated tumours [29]. As 
advanced prostate cancer is often accompanied by androgen escape this suggests that 
Akt activity may be up-regulated in androgen insensitive clinical specimens [33]. 
These data are however, inconclusive, and to date no comparison has been made 
between androgen sensitive and insensitive tissue from the same patient.   
PKC is a phospholipid-dependent cytoplasmic, serine/theronine kinase, which 
may be activated by TGF-β, phorbolesters e.g. phorbol 12-myristate 13-acetate 
(PMA) or intercellular activators such as calcium and diacylglycerol [34](Fig. 3).  
There are PKC phosphorylation consensus sites on the AR at Ser81, 650 [35] and PMA 
treatment has been reported to increase the phosphorylation of AR at Ser650 [35]. This 
suggests that activation of PKC signalling can affect AR phosphorylation.  However 
there is again little clinical evidence, at present, to support a role of PKC in 
development of androgen escape and the PKC phosphorylation consensus sites on the 
AR are also phosphorylated when DHT binds [35].  It may therefore be the case that 
phosphorylation of the AR at Ser81, 650 may be required for activation of the receptor, 
via DHT binding. 
In summary, a number of signalling pathways act, either synergistically or in 
isolation, to modify AR activity through phosphorylation at multiple distinct sites. AR 
phosphorylation both stabilises and modifies activity of the receptor and whilst there 
is strong evidence for both activities the specific role of many phosphorylation sites 
remains unclear at present. Whilst clinical androgen escape may be a result of 
sensitisation of the prostate cancer cell to low circulating levels of androgens present 
during maximum androgen blockade, achieved via either AR stabilisation or 
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activation through this mechanism, clinical evidence for these pathways being active 
in vivo remains sparse.  However, sufficient evidence exists to suggest that hormone 
escape may be mediated via phosphorylation of the AR by a variety of kinases 
including MAP kinase and Akt.  Further in vivo investigations are required to confirm 
this and to identify which of these pathways may provide specific molecular targets 
for future therapeutic intervention. 
CONCLUSION 
Whilst androgen ablation therapy is a highly successful for hormone sensitive prostate 
cancer, the rapid onset of hormone resistance in the majority of cases significantly 
limits the benefits derived from this therapy. Currently there is no effective standard 
treatment for androgen resistant prostate cancer. Previously research efforts have 
suggested that molecular modification of the AR gene was likely to underlie 
development of androgen escape. However, within the past 5 years we have witnessed 
a major shift in our understanding of the mechanisms underlying androgen escape. It 
is now apparent that the control of AR function involves post-translational 
modification, generally via phosphorylation by various kinase) cascades.  
Currently evidence from the literature suggests that the dominant pathways 
involved in the development of androgen escape are the MAP kinase and PI3K 
pathways (Fig. 3). These pathways act to directly modify the AR, altering its 
sensitivity to both androgens and anti-androgens.  The pluripotent nature of these 
pathways suggests that molecular targeting of specific kinases (e.g. AKT or MAP 
kinase) within these pathways could reverse hormone resistance via several 
mechanisms. Further research into the role of these pathways in clinical samples 
should be the immediate focus for future research.  
 14 
However, despite the current shift away from molecular targeting of the AR it 
should be remembered that one in five hormone resistant prostate cancers show AR 
gene amplification, this may lead to screening of patients for AR amplification prior 
to implementation of therapies.  
Perhaps the most significant advance in our understanding of the molecular 
genetics of hormone relapse is the recognition that, with multiple pathways being 
shown to be involved in this process, the hormone resistant tumour population must 
represent several molecular sub-groupings. In effect the AR amplified patient cohort 
(20%) identified the first molecular sub-typing of this disease.  Data from molecular 
profiling of hormone resistant prostate cancer identifies separate groupings with 
activation of the Ras/Raf/MAP kinase and Akt/PI3K pathways. Each of these 
molecular sub-groups is likely to require a separate therapeutic approach. It therefore 
now seems likely that future therapy for prostate cancer could involve profiling of 
individual tumours in order to identify appropriate therapies. Matching the therapeutic 
agents to the molecular profile of the tumour has proven to be a highly effective 
strategy in other cancers. If this approach can be successfully applied to prostate 
cancer we may, at last, see significant therapeutic benefit for hormone relapsed 
prostate cancer sufferers.   
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 FIGURE LEGENDS 
Figure 1 shows how testosterone (T) enters the prostate epithelial cell and is 
converted to dihydrotestosterone (DHT) which binds to and activates the androgen 
receptor (AR).  HSP denotes heat shock proteins and P denotes phosphorylation. 
Figure 2 shows kaplan-meier curves for patients with and without AR gene 
amplification (Figure 2 a) and AR protein expression (figure 2b). 
Figure 3 shows how the MAP kinase, Akt and PKC pathways impacts prostate cancer 
growth. AR denotes androgen receptor, HSP denotes heat shock proteins, and P 
denotes phosphorylation. 
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